Cut Timelines and Costs in Late-Phase Oncology: Why Asia Should Be Your Next Trial Destination

Advanced Technology Infrastructure

Asian countries are often ahead of Western markets in adopting the latest clinical trial technologies. The region offers sophisticated electronic health records integration, advanced telemedicine platforms, and data analytics capabilities that ease the burden of trial management while improving data accuracy. Many sites provide robust infrastructure for decentralized trial components, including remote patient monitoring, digital consent processes, and mobile health applications that enhance patient engagement and retention.

This technological sophistication, combined with high smartphone penetration rates and digital literacy, creates opportunities for innovative trial designs that can further reduce costs and accelerate timelines.

Streamlined Regulatory Pathways

Regulators across Asia are proactively making clinical research accessible to global sponsors. Both South Korea and Taiwan offer mature, harmonized frameworks designed to streamline the pathway to IND approval:

• South Korea’s Ministry of Food and Drug Safety (MFDS)** leverages a five-step IND approval process, with a review time of 30 business days.⁶
• Taiwan Food and Drug Administration (TFDA)** standard IND review takes approximately 45 days.⁷ However, Taiwan’s fast-track process for multiregional trials, the Multinational Clinical Trial Notification Scheme (CTN), can reduce review time to just 14 days if the protocol has already been approved by regulatory authorities in the U.S., U.K., Australia, France, Japan, Switzerland, Canada, or Sweden.⁸

These streamlined timelines represent significant advantages over traditional markets, where regulatory reviews can extend 60-90 days or longer.

Cost Advantages Without Compromising Quality

Trials held in Asian countries typically cost 30% to 40% less than those held in the U.S. and Europe, enabling sponsors to better allocate their resources and maintain budgets.⁵ These savings stem from lower operational costs, competitive investigator fees, and efficient site operations, not from compromised quality standards.

Countries like South Korea and Taiwan are home to world-class research and oncology centres run by key opinion leaders (KOLs) and highly-trained medical professionals who maintain rigorous Good Clinical Practice (GCP) compliance. Major institutions such as Samsung Medical Centre in Seoul and National Taiwan University Hospital operate under international quality standards, with many sites holding accreditations from organizations like AAHRPP (Association for the Accreditation of Human Research Protection Programs).

Addressing Common Concerns

Quality and Compliance: While cost savings are attractive, sponsors rightfully prioritize data quality and regulatory compliance. Leading Asian clinical trial sites maintain international GCP standards through regular training, robust monitoring systems, and ongoing quality assurance programs. Many sites undergo regular inspections by international regulatory authorities and maintain certifications equivalent to those found in traditional Western markets.

Cultural and Communication Considerations: Successful Asian expansion requires understanding local healthcare practices, patient expectations, and regulatory nuances. Language barriers, cultural differences in informed consent processes, and varying approaches to patient-physician relationships must be carefully navigated with experienced local partners.

Regulatory Fragmentation: While individual countries like South Korea and Taiwan offer streamlined processes, the broader Asian market remains fragmented with varying requirements across jurisdictions. Success requires strategic site selection and regulatory expertise specific to each target market.

How Avance Clinical Empowers Trial Success In Asia

At Avance Clinical, a global CRO headquartered in Australia, our team launched dedicated operations in Asia, enabling our partners to reap the benefits of expanded recruitment and substantial cost savings while maintaining the highest quality standards.

Strategic Market Presence: We maintain operational hubs in South Korea and Taiwan, both markets recognized for their commitment to advanced technology and clinical trial excellence. Our regulatory specialists assist clients in seamless preparation of regulatory packages to secure rapid IND approval from either the MFDS or TFDA, while our local clinical teams help sites navigate resource allocation and recruitment optimization.

Established Site Networks: Avance Clinical has established memorandums of understanding (MOUs) with top oncological clinical sites in both countries. These partnerships provide sponsors priority access to eligible patients and accelerate finalization of clinical trial agreements (CTAs) to maintain demanding timelines. Our relationships with key opinion leaders in both countries inform strategic site selection and provide critical insights into local patient populations and treatment patterns.

Quality Assurance: With extensive experience running global oncology trials, we ensure clients maintain full compliance with the latest regulatory guidance while leveraging local advantages. Our quality management systems are designed to meet international standards, with regular auditing and monitoring protocols that satisfy the most stringent regulatory requirements.

Technology Integration: We leverage cutting-edge clinical trial technologies available in Asian markets, including advanced data management systems, electronic health records integration, and digital patient engagement platforms that enhance trial efficiency while maintaining data integrity.

Success Metrics and Real-World Impact

Our clients typically experience 25-35% cost savings when incorporating Asian sites into their late-phase oncology programs, with recruitment timelines reduced by 30-50% compared to Western-only studies. Patient retention rates often exceed 90% due to strong physician-patient relationships and comprehensive support systems available at leading Asian medical centres.

The combination of cost efficiency, rapid enrolment, and high-quality data generation creates compelling value propositions for sponsors facing increasing pressure to demonstrate both clinical and commercial success.

What’s The Next Step?

For U.S. oncology drug sponsors looking to reduce costs, increase speed, and reach their patient recruitment goals in clinical trials, expanding your late-phase trial to Asia offers proven advantages. However, success requires more than simply adding Asian sites, it demands strategic planning, local expertise, and rigorous quality management.

As you evaluate whether Asian expansion is right for your clinical program, consider how partnering with an experienced global CRO can help you maximize the benefits of these growing markets while navigating operational complexities and maintaining the highest quality standards. The future of efficient, cost-effective oncology drug development increasingly points East, and the question isn’t whether to expand into Asia, but how quickly and strategically you can make that transition.